<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04297488</url>
  </required_header>
  <id_info>
    <org_study_id>CACTGUT20</org_study_id>
    <nct_id>NCT04297488</nct_id>
  </id_info>
  <brief_title>Probiotic Supplementation for Those Immune Non-responders With HIV-1 Infection</brief_title>
  <official_title>Effect and Safety of Probiotic Supplementation in Immune Non-responders With HIV-1 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking Union Medical College Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking Union Medical College Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Up to 25% of HIV-infected individuals receiving antiretroviral treatment demonstrate
      suboptimal blood CD4 recovery despite effective viral suppression; this &quot;immunologic
      non-responder&quot; (INR) phenotype is associated with increased immune activation and with higher
      rates of AIDS and non-AIDS related conditions, and death. Poor gut integrity, increased
      microbial translocation, and reduced CD4 T-cell trafficking to the gut could be a source of
      ongoing inflammation in INR individuals. Researches have shown that the gut microbiota
      compositions are different in INRs and immunological responders (IRs). Probiotics, by
      modulation of gut microbiota, can help induce epithelial healing and prevent bacterial
      translocation. Probiotic supplementation, therefore, may be a nutritional target for INRs by
      boosting CD4 cell counts. We design a prospective, case-control, self-contrast study to
      explore the efficacy and safety of probiotic supplementation in INRs. Participants will
      receive oral probiotic containing 3 billion Bifidobacterium and 1 billion Lactobacillus once
      daily. Gut bacterial community diversity and composition, immune recovery and activation in
      peripheral plasma/mucosa, plasma levels of gut damage, microbial translocation and
      inflammation at baseline and after 6 months of receiving intervention will be analyzed.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2020</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune recovery and activation</measure>
    <time_frame>Changes from baseline to 6 months</time_frame>
    <description>CD4+ T-cell and CD8+ T-cell counts, CD4/CD8 ratio, CD38+/HLA-DR+ CD8+/CD4+ T cell ratio</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Plasma levels of gut damage, microbial translocation and inflammation</measure>
    <time_frame>Changes from baseline to 6 months</time_frame>
    <description>IL-8, IL-1β, IL-6, TNF-α, CRP, D-dimer, I-FABP, LPS, LBP, sCD14, sCD40L, and IDO (Kynurenine/Tryptophan ratio)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood viral load</measure>
    <time_frame>Changes from baseline to 6 months</time_frame>
    <description>HIV-RNA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolic measurements from blood plasma</measure>
    <time_frame>Changes from baseline to 6 months</time_frame>
    <description>Vitamin D, glucose and insulin, and lipid profiling</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Feasibility, safety, tolerability, adherence, and acceptability of study product and procedures</measure>
    <time_frame>Changes from baseline to 6 months</time_frame>
    <description>Based on patients' description and intervention-related adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut bacterial community diversity and composition</measure>
    <time_frame>Changes from baseline to 6 months</time_frame>
    <description>Bacterial community diversity and composition determined by16S rRNA gene sequencing of fecal samples</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>HIV-infection/Aids</condition>
  <arm_group>
    <arm_group_label>INR</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive oral probiotic capsules containing 3 billion Bifidobacterium and 1 billion Lactobacillus once daily for 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Bifidobacteria and Lactobacilli triple viable capsules</intervention_name>
    <description>Bifidobacteria and Lactobacilli triple viable capsules (provided by Shenzhen Wanhe Pharmaceutical Co., Ltd., China) are bilayer minipellets and are resistant to gastric acid. So Bifidobacterium billion Lactobacillus can only be released in intestine. Participants will take 1.27g (contain 3 billion Bifidobacterium and 1 billion Lactobacillus) once daily.</description>
    <arm_group_label>INR</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Documented HIV-1 infection

          -  18-65 years old

          -  On antiretroviral therapy (&gt;2 years)

          -  Ability to provide informed consent

          -  Undetectable plasma HIV-1 viral load for the past 2 years

          -  CD4 T-cell count &lt;350/mm3 for the last 2 years

          -  No history of gastrointestinal diseases

        Exclusion Criteria:

          -  Administration of antibiotics, probiotics, or prebiotics or experience of diarrhea
             within the previous 3 months;

          -  Administration of anti-inflammatory drugs, corticosteroids, immunosuppressive drugs,
             immunomodulator within the previous 3 months;

          -  Severe organ dysfunction

          -  Pregnancy or breastfeeding
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wei LYU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking Union Medical College Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Qing Zhang</last_name>
    <phone>+86-13207572893</phone>
    <email>1214345667@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Peking Union Medical College Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>June 8, 2018</study_first_submitted>
  <study_first_submitted_qc>March 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2020</study_first_posted>
  <last_update_submitted>March 3, 2020</last_update_submitted>
  <last_update_submitted_qc>March 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

